Genmab — December 2025
-
Genmabs partner får udvidet godkendelse til lungekræftmiddel fra FDA https://proinvestor.com/investornyt/1394808/genmabs-partner-far-udvidet-godkendelse-til-lungekraeftmiddel-fra-fda
-
subcutaneous - U.S. FDA Approval of RYBREVANT FASPRO
(amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE
(lazertinib) https://www.jnj.com/media-center/press-releases/u-s-fda-approval-of-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-enables-the-simplest-shortest-administration-time-for-a-first-line-combination-regimen-when-combined-with-lazcluze-lazertinib -
RAINFOL-05 ! New trial - Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer https://clinicaltrials.gov/study/NCT07288177
-
Genmab’s Rina-S: New Study Targets Lung Cancer with Innovative Treatment https://www.tipranks.com/news/company-announcements/genmabs-rina-s-new-study-targets-lung-cancer-with-innovative-treatment
-
Kort video: De amerikanske aktier, som er lokomotivet for det globale aktiemarked, har været negative de sidste fire-fem dage. Helge Larsen fortæller om årsagerne og kigger derudover selskabsspecifikt på Anavex, som skal til reeksamen, Bavarian Nordics fremtid, opdatering på Novo Nordisk og Genmab, og til sidst Zealand Pharma, hvor der torsdag er Q&A med CEO Adam Steensberg https://proinvestor.com/boards/130406
-
yesterday : Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-announces-positive-preliminary-phase-1-data --> PYXS fell 48% on this
-
How Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes https://healthmedicinet.com/hmn-2025-how-adding-epcoritamab-standard-line-therapy/ "We will not know for a long time if [this regimen] is curative, but it’s certainly the beginning of a bright era for chemo-free therapy for follicular lymphoma.”
-
Juleaftensdag holder Proinvestor redaktion for en sjælden gangs skyld fri. Vi er på igen torsdag 1. juledag med optagelse og udsendelse af Ugevideoen samt nyhedsbrev med fyldig omtale og perspektivering af Novos tidlige julegave med FDA´s godkendelse af Wegovy vægttabstablet. 2. juledag fredag byder vi på denne længere video-julespecial hvor jeg tager Larsen en nørdet snak med Pila Pharma’s grundlægger og forskningsdirektør, Dorte X. Gram - om hendes tid som forsker hos Novo Nordisk
-
Du kommer med i kulissen bag udviklingen fedmemidler, opdagelsen af semaglutid og de helt spæde GLP-1 skridt på Novo Nordisk!
-
Promising Therapy for Hard-to-treat DLBCL: Epcoritamab + GemOx #DLBCL | Joshua Brody, MD | #ASH2025 https://www.youtube.com/watch?v=HxPPVK6DJWs
-
J&J-data giver særbehandling fra FDA-chef https://proinvestor.com/investornyt/1397504/ugens-grafik-2-jampj-data-giver-saeligrbehandling-fra-fda-chef
-
Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared https://pj.jiho.jp/article/254456
-
Godmorgen
-
Genmab to discontinue clinical development of acasunlimab following a portfolio review
Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and increasingly competitive landscape
This decision does not impact Genmab’s full‑year 2025 financial guidance
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind